-
1
The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
Published 2024-09-01Subjects: Get full text
Article -
2
-
3
Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
Published 2025-01-01Subjects: “…Renal cell carcinoma; Tyrosine kinase inhibitor…”
Get full text
Article -
4
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
Published 2024-12-01Subjects: Get full text
Article -
5
Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
Published 2025-01-01Subjects: Get full text
Article -
6
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
Published 2025-01-01Subjects: Get full text
Article -
7
-
8
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
Published 2025-02-01Subjects: Get full text
Article -
9
-
10
-
11
Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
Published 2025-02-01Subjects: “…Tyrosine kinase inhibitor…”
Get full text
Article -
12
-
13
Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
Published 2025-01-01Subjects: Get full text
Article -
14
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
Published 2024-03-01Subjects: Get full text
Article -
15
A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
Published 2024-07-01Subjects: Get full text
Article -
16
Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case
Published 2025-02-01Subjects: Get full text
Article -
17
-
18
Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India
Published 2023-07-01Subjects: Get full text
Article -
19
Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
Published 2025-03-01Subjects: Get full text
Article -
20